Weave Bio Secures $20 Million Series A

Weave Bio Secures $20 Million Series A

Weave Bio, a San Francisco, CA–based AI-native regulatory automation management solutions company, has secured $20 million in Series A funding.

The round was led by USVP, with participation from Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital.

USVP is a Silicon Valley venture capital firm founded in 1981 and headquartered in Menlo Park, California. The firm specializes in early-stage Series A and B investments across the technology and healthcare sectors. USVP’s core investment domains include cybersecurity, enterprise/cloud software (SaaS), consumer internet and e-commerce, and healthcare.

The company will use the funding to enhance its AI-driven platform, expand into global regulatory markets, achieve full coverage of the therapeutic lifecycle, and grow its commercial team.

Led by CEO Brandon Rice, Weave Bio is an AI-native, cloud-based software company that provides an AI-native solution built to support regulatory workflows across the entire therapeutic lifecycle from IND preparation through market applications and post-market updates. Designed for pharmaceutical companies, biotech firms, CROs, and regulatory consultants, Weave infuses AI into every step from data extraction to dossier submission to deliver compliant, submission-ready documents with unprecedented speed. Founded in 2022, Weave Bio is headquartered in San Francisco, California.

Funding Details

Company: Weave Bio

Raised: $20.0M

Round: Series A

Funding Date: October 2025

Lead Investor: USVP

Additional Investors: Innovation Endeavors, Magnetic Ventures, Character, TMV, Serrado Capital

Company Website: https://www.weave.bio/

Software Category: Healthtech / Regulatory Automation